An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
NCT00228059
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
132
Enrollment
INDUSTRY
Sponsor class
Conditions
Bipolar I Disorder
Interventions
DRUG:
Licarbazepine
Sponsor
Novartis